GlassScriptPhysician profile
Antonio Wong
NPI 1932206315
$4,963.26
in general payments reported to CMS, 2019-2025
27 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $397 · 2021: $734 · 2022: $1,159 · 2023: $938 · 2024: $733 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $658.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $602.83 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $352.66 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $350.51 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Astellas Pharma US INC | $345.92 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.74 | 2019-2025 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $338.94 | 2019-2025 | Xifaxan, Trulance |
| Ironwood Pharmaceuticals, INC | $332.48 | 2019-2025 | Linzess |
| Astrazeneca Pharmaceuticals LP | $311.91 | 2019-2025 | Farxiga |
| Amarin Pharma, INC. | $193.07 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $177.60 | 2023-2025 | Rexulti |
| Pfizer INC. | $159.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $151.09 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $110.32 | 2019-2023 | |
| Optinose US, INC. | $101.72 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $73.33 | 2019-2024 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $71.54 | 2020-2023 | |
| Ardelyx, INC. | $53.68 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $46.72 | 2022 | |
| Abbott Laboratories | $38.03 | 2023-2025 | Freestyle Libre |
| Allergan, INC. | $32.04 | 2020 | |
| Phathom Pharmaceuticals, INC. | $31.85 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $24.20 | 2021 | |
| Dexcom, INC. | $16.62 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $16.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.21 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.